Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.74 |
| ▸ | POLB | P06746 | 3/20 | 0.67 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.62 |
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.59 |
| ▸ | KDM1A | O60341 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | RAD52 | P43351 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL28295097 | 0.98 | CYP2C19 (0.72) | CYP2C19CYP3A4CYP2D6POLBSIGMAR1 | |
| SCHEMBL14068495 | 0.97 | CYP2C19 (0.70) | CYP2C19CYP3A4CYP2D6POLBSIGMAR1 | |
| SCHEMBL3175221 | 0.92 | CYP2C19 (0.80) | CYP2C19CYP3A4CYP2D6POLBSIGMAR1 | |
| SCHEMBL39631 | 0.90 | DPP7 (0.73) | CYP2C19CYP3A4CYP2D6POLBSIGMAR1 | |
| Hydrochloric Acid SCHEMBL7000083 | 0.89 | DPP7 (0.71) | CYP2C19CYP3A4CYP2D6POLBSIGMAR1 | |
| Hydrochloric Acid SCHEMBL5758788 | 0.89 | DPP7 (0.71) | CYP2C19CYP3A4CYP2D6POLBSIGMAR1 | |
| SCHEMBL3179723 | 0.89 | CYP2C19 (0.76) | CYP2C19CYP3A4CYP2D6POLBSIGMAR1 | |
| SCHEMBL2444736 | 0.89 | DPP7 (0.69) | CYP2C19CYP3A4CYP2D6SIGMAR1KMT2A | |
| SCHEMBL3181015 | 0.88 | CYP2C19 (0.74) | CYP2C19CYP3A4CYP2D6POLBKMT2A | |
| SCHEMBL3181193 | 0.85 | CYP2C19 (0.70) | CYP2C19CYP3A4CYP2D6POLBSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190084981-A1 | Bromodomain Inhibitors | ABBVIE INC (US) | 2019-03-21 | — | — | US | disclosed |
| US-10131657-B2 | Bromodomain inhibitors | ABBVIE INC. (US) | 2018-11-20 | — | — | US | disclosed |
| US-10093624-B2 | NAMPT and ROCK inhibitors | ABBVIE INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-9957263-B2 | Bromodomain inhibitors | ABBVIE INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20160272630-A1 | Bromodomain Inhibitors | ABBVIE INC. (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160185769-A1 | Bromodomain Inhibitors | ABBVIE INC. (US) | 2016-06-30 | — | — | US | disclosed |
| CN-105531273-A | Bromodomain inhibitors | ABBVIE INC | 2016-04-27 | — | — | CN | disclosed |
| CN-105518007-A | BROMODOMAIN INHIBITORS | ABBVIE INC | 2016-04-20 | — | — | CN | disclosed |
| US-9302989-B2 | NAMPT and rock inhibitors | ABBVIE INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20160031880-A1 | Nampt and Rock Inhibitors | ABBVIE INC. (US) | 2016-02-04 | — | — | US | disclosed |
| US-20120122842-A1 | NAMPT AND ROCK INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
| US-6025489-A | Tricyclic pteridinones and a process for their preparation | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-02-15 | — | — | US | disclosed |
| EP-0429149-B1 | Tricyclic pteridinones and a process for their preparation | BERLEX LAB (US) | 2000-01-05 | — | — | EP | disclosed |
| US-5854419-A | Tricyclic pteridinones and a process for their preparation | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-12-29 | — | — | US | disclosed |
| US-5602252-A | Tricyclic pteridinones and a process for their preparation | BERLEX LABORATORIES, INC. | 1997-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10093624-B2 | NAMPT and ROCK inhibitors | NAMPT, NNMT, NADK | CYP2C19 4209/4885CYP3A4 4172/4885CYP2D6 4416/4885 |
| US-20120122842-A1 | NAMPT AND ROCK INHIBITORS | NAMPT, NNMT, NME2 | CYP2C19 4667/4885CYP3A4 4721/4885CYP2D6 4653/4885 |
| US-20190084981-A1 | Bromodomain Inhibitors | BRD4, BRD1, BRD3 | CYP2C19 3474/4885CYP3A4 3209/4885CYP2D6 3067/4885 |
| US-10131657-B2 | Bromodomain inhibitors | BRD1, BRD4, BRD3 | CYP2C19 3332/4885CYP3A4 2970/4885CYP2D6 2821/4885 |
| US-20160272630-A1 | Bromodomain Inhibitors | BRD4, BRDT, EP300 | CYP2C19 4047/4885CYP3A4 3813/4885CYP2D6 3858/4885 |
| US-20160185769-A1 | Bromodomain Inhibitors | BRD1, BRD4, BRD3 | CYP2C19 3332/4885CYP3A4 2970/4885CYP2D6 2821/4885 |
| US-20160031880-A1 | Nampt and Rock Inhibitors | NAMPT, NNMT, NME2 | CYP2C19 4667/4885CYP3A4 4721/4885CYP2D6 4653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.